| abstract |
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Thus, the present invention would benefit from modulating PD-1, PD-L1, and / or PD-L2 activity using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein. A composition and method for diagnosing, prognostic observation, and treating a condition (eg, persistent infectious disease, autoimmune disease, asthma, transplant rejection, inflammatory disease and tumor). |